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ATBACKGROUND & AIMS: Excess and unresolved endoplasmic
reticulum (ER) stress in intestinal epithelial cells (IECs) pro-
motes intestinal inflammation. Activating transcription factor 6
(ATF6) is one of the signaling mediators of ER stress. We
studied the pathways that regulate ATF6 and its role for
inflammation in IECs. METHODS: We performed an RNA
interference screen, using 23,349 unique small interfering
RNAs targeting 7783 genes and a luciferase reporter controlled
by an ATF6-dependent ERSE (ER stress-response element)
promoter, to identify proteins that activate or inhibit the ATF6
signaling pathway in HEK293 cells. To validate the screening
results, intestinal epithelial cell lines (Caco-2 cells) were
transfected with small interfering RNAs or with a plasmid
overexpressing a constitutively active form of ATF6. Caco-2
cells with a CRISPR-mediated disruption of autophagy related
16 like 1 gene (ATG16L1) were used to study the effect of ATF6on ER stress in autophagy-deficient cells. We also studied in-
testinal organoids derived from mice that overexpress consti-
tutively active ATF6, from mice with deletion of the autophagy
related 16 like 1 or X-Box binding protein 1 gene in IECs
(Atg16l1DIEC or Xbp1DIEC, which both develop spontaneous
ileitis), from patients with Crohn’s disease (CD) and healthy
individuals (controls). Cells and organoids were incubated with
tunicamycin to induce ER stress and/or chemical inhibitors of
newly identified activator proteins of ATF6 signaling, and
analyzed by real-time polymerase chain reaction and immu-
noblots. Atg16l1DIEC and control (Atg16l1fl/fl) mice were given
intraperitoneal injections of tunicamycin and were treated with
chemical inhibitors of ATF6 activating proteins. RESULTS: We
identified and validated 15 suppressors and 7 activators of the
ATF6 signaling pathway; activators included the regulatory
subunit of casein kinase 2 (CSNK2B) and acyl-CoA synthetase
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
Endoplasmic reticulum stress in intestinal epithelial cells
promotes intestinal inflammation. Activating transcription
factor 6 (ATF6) is one of the cellular mediators of the ER
stress response.
NEW FINDINGS
Ileal epithelial cells from patients with CD have higher
levels of activated ATF6, which is regulated by CSNK2B
and ACSL1. ATF6 increases expression of tumor
necrosis factor and other inflammatory cytokines in
response to endoplasmic reticulum stress in intestinal
cells.
LIMITATIONS
This study was performed in cell lines, tissues from
patients, and mice; further studies of this pathway are
needed in humans.
IMPACT
Strategies to inhibit ATF6 signaling pathway might be
developed for treatment of inflammatory bowel diseases.




ATlong chain family member 1 (ACSL1). Knockdown or chemical
inhibition of CSNK2B and ACSL1 in Caco-2 cells reduced ac-
tivity of the ATF6-dependent ERSE reporter gene, diminished
transcription of the ATF6 target genes HSP90B1 and HSPA5 and
reduced NF-kB reporter gene activation on tunicamycin stim-
ulation. Atg16l1DIEC and or Xbp1DIEC organoids showed
increased expression of ATF6 and its target genes. Inhibitors of
ACSL1 or CSNK2B prevented activation of ATF6 and reduced
CXCL1 and tumor necrosis factor (TNF) expression in these
organoids on induction of ER stress with tunicamycin. Injection
of mice with inhibitors of ACSL1 or CSNK2B significantly
reduced tunicamycin-mediated intestinal inflammation and IEC
death and expression of CXCL1 and TNF in Atg16l1DIEC mice.
Purified ileal IECs from patients with CD had higher levels of
ATF6, CSNK2B, and HSPA5 messenger RNAs than controls;
early-passage organoids from patients with active CD show
increased levels of activated ATF6 protein, incubation of these
organoids with inhibitors of ACSL1 or CSNK2B reduced tran-
scription of ATF6 target genes, including TNF. CONCLUSIONS:
Ileal IECs from patients with CD have higher levels of activated
ATF6, which is regulated by CSNK2B and HSPA5. ATF6 in-
creases expression of TNF and other inflammatory cytokines in
response to ER stress in these cells and in organoids from
Atg16l1DIEC and Xbp1DIEC mice. Strategies to inhibit the ATF6
signaling pathway might be developed for treatment of in-
flammatory bowel diseases.Keywords: IBD; Inflammation; Signal Transduction; Gene
Expression.
he endoplasmic reticulum (ER) is a tightlyAbbreviations used in this paper: ACSL1, Acyl-CoA Synthetase Long
Chain Family Member 1; ATF6, activating transcription factor 6; Atg16l1,
autophagy related 16 like 1; CD, Crohn’s disease; CSNK2B, casein kinase
2 beta; ER, endoplasmic reticulum; ERSE, ER-stress response elements;
GRP78, glucose-regulated protein 78 kDa; IBD, inflammatory bowel dis-
ease; IECs, intestinal epithelial cells; IRE1, endoribonuclease inositol-
requiring enzyme 1; mRNA, messenger RNA; NF-kB, nuclear factor kap-
paB; PCR, polymerase chain reaction; S1P/S2P, site 1/2 protease; SI,
small intestine; siRNA, small interfering RNA; TBB, 4,5,6,7-Tetrabromo-2-
azabenzimidazole; TC, Triacsin C; TNF, tumor necrosis factor; UPR,
unfolded protein response; WT, wild type; Xbp1, X-box binding protein 1.
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https://doi.org/10.1053/j.gastro.2020.06.088Tcontrolled cellular compartment for synthesis and
folding of secretory proteins. Accumulation of unfolded/
misfolded proteins within the ER provokes an unfolded
protein response (UPR) with the aim to reduce ER stress and
restore homeostasis. Unresolved ER stress can lead to
excessive UPR activation, which can be inflammatory and
ultimately lead to programmed cell death.1 Three main arms
govern the ER-stress–induced response in mammalian cells,
regulated by 3 key molecules, respectively: IRE1a (endor-
ibonuclease inositol-requiring enzyme 1a), PERK (protein
kinase RNA-like ER kinase), and ATF6a.2,3 These 3 proximal
transmembrane sensors are activated by dissociation of the
ER chaperone glucose-regulated protein 78 (GRP78) in favor
of binding to misfolded proteins. Unbound ATF6a trans-
locates to the Golgi network, where it undergoes regulated
intramembrane proteolysis mediated by the site 1 and site 2
protease (S1P/S2P). The released cytosolic N-terminal
portion of ATF6a migrates to the nucleus and induces the
expression of genes containing ER-stress response elements
(ERSE-I and -II) (eg, GRP78).4 Recent findings indicate that
activation of the UPR induces macroautophagy and that
autophagy in turn is able to alleviate the UPR.5–9 A strong
link for an impaired UPR/autophagy crosstalk has been
identified in the etiopathogenesis of inflammatory bowel
disease (IBD), by both functional and genetic evidence.7,8,10–
12 Conditional deletion of XBP1 in the intestinal epithelium
leads to paradoxical activation of ER stress and aspontaneous enteritis in mice.8 Likewise, mice with a con-
ditional intestinal epithelial deletion of the Crohn’s disease
(CD) risk gene autophagy related 16 like 1 (ATG16L1), a core
component of the autophagic machinery, display signs of
unresolved ER stress, impaired Paneth cell architecture and
suffer from spontaneous, age-dependent onset of ileitis.13
The models share increased proinflammatory signals via
nuclear factor (NF)-kB, high levels of tumor necrosis factor
(TNF)a secretion, increased necroptotic epithelial cell death,
and accumulation of IRE1a,5,13,14 reflecting molecular al-
terations observed in patients with IBD.
Surprisingly little is known about the executioners of the
inflammatory signaling under conditions of hyperactivated ER
stress. Importantly, although the downstream transcriptional
program induced by ATF6a signaling has been extensively
studied in the context of ER homeostasis,15,16 our knowledge
regarding the exact regulatory network of the ATF6 branch
within the intestinal epithelium is still limited. We hypothe-
sized that modulation of ATF6a function might counteract
detrimental signals of aggravated ER stress in IECs, specifically
in conditions of genetically disturbed autophagy.
Figure 1. Systematic siRNA screening reveals modulators of ATF6a activation. (A) Schematic representation of the screening
approach. (B) Screening procedure and number of candidates at different screening stages. In the primary and secondary
screens each gene was targeted with 3 individual siRNAs tested separately. Pools of 4 siRNAs were used for the third screen.
Candidate genes with an inducing or repressing effect on ATF6 activation are indicated in green or orange, respectively. (C)
Final set of 22 candidates after the third screen. Bars depict mean and 95th confidence interval (3 replicates). (D) STRING
Network of candidate genes (third screen). Only interactions with a confidence score >0.4 were considered. Inducers depicted
in green, repressors shown in orange. (E–H) ERSE promoter activity quantified by dual luciferase reporter assay in HEK-293
cells. N ¼ 6. Cells were exposed to tunicamycin (5 mg/mL) and small molecule agents for 24 hours. Depicted data repre-
sentative of 3 independent experiments. Statistical analysis was performed using 1-way analysis of variance together with
Tukey post hoc test. TPEN, N,N,N0,N0-Tetrakis(2-pyridylmethyl)ethylenediamine; CM, Camostat mesylate; Sim, Simvastatin.













ATIn this study, we set out to systematically under-
stand modulators of ATF6a signaling using a stringent
high-throughput RNA interference screening. Among the
validated hits, 2 upstream co-activators of ATF6a
signaling were identified and further validated: Acyl-CoA
Synthetase Long Chain Family Member 1 (ACSL1) and
the casein kinase 2 beta (CSNK2B). Using primary mu-
rine intestinal organoid cultures, we show that impair-
ment of autophagy or unresolved ER stress in IECs
results in the compensatory up-regulation of the ATF6a
branch, which we link to enhanced proinflammatory
signaling and cytokine secretion, which could be
restricted by inhibition of ACSL1 or CSNK2B in vitro and
in vivo. Our findings point to upstream inhibition of
ATF6a as a novel therapeutic strategy to overcome
detrimental proinflammatory effects of failing autophagy
and the UPR in IECs.Materials and Methods
Cell Culture and Reagents
Information on cell culture and reagents can be found in the
supplementary material.
Cultivation of Murine Small Intestine Organoids
Crypts were isolated from mouse small intestine (SI) by
EDTA-based Ca2þ/Mg2þ chelation and intestinal organoids
were cultivated as described by Sato et al.17
Culture of Human Intestinal Organoids
Human intestinal biopsy specimens were obtained from
patients who underwent endoscopic examination. The study
was approved by the Ethics Committee of the Medical Faculty,
University Kiel (vote B231/98) and written informed consent
was obtained from each patient prior to study related
Figure 1. Continued.




ATprocedures. Isolation of the crypts and establishment of intes-
tinal organoids were performed as described.18 Organoids were
passaged every 6 to 7 days. For all experiments, organoids were
used at passage 3 to 5.High-Throughput RNA Interference Screening
Procedure
A total of 23,349 unique small interfering RNAs (siRNAs)
targeting 7783 genes were screened using the Silencer Human
Druggable Genome siRNA library V3 (Ambion, Austin, TX). HEK-
293 cells were reverse transfected with either single siRNAs
(Ambion; primary and secondary screen) or siRNA pools (siGE-
NOME; SMARTpool; Dharmacon, Lafayette, LA; tertiary screen)
complexed with siPORT Amine (Ambion) as described.19Dual Luciferase Reporter Assays
Plasmid-encoded ERSE-dependent firefly luciferase (pGL3-
ERSE, 12 ng/well) and a constitutive thymidine-kinase driven
Renilla luciferase were used in a dual luciferase assay (Clontech,
3 ng/well) to assay ATF6/ERSE activation. For quantification of
the NF-kB promoter activity, a reporter system based on NF-kB
responsive promoter elements driving expression of the Firefly
luciferase (40 ng/well) was used.19 For all luciferase reporter
assays, the fold change is depicted. For calculating the fold
change, unstimulated wild-type (WT) controls were set to 1.RNA Extracts and Quantitative Real-Time
Polymerase Chain Reaction
Total RNA was isolated using the RNeasy kit (Qiagen,
Hilden, Germany). Total RNA was reverse-transcribed to
complementary DNA using the Maxima H Minus First
Strand cDNA Synthesis kit (Thermo Scientific, Waltham,
MA). Quantitative real-time polymerase chain reaction
(PCR) was performed using the TaqMan Gene Expression
Master Mix (Applied Biosystems, Foster City, CA) and
analyzed by the 7900HT Fast Real-Time PCR System
(Applied Biosystems). The following TaqMan assays
(Applied Biosystems) were used: ACSL1(00960561),
CSNK2B(00365635), ATF6(00232586), HSP90B1(00427665),
DNAJC3(00534483), Hsp90b1(00441926),
Hspa5(00517690), and Tnf(00443258). Relative transcript
levels were determined using the indicated housekeeper
and the standard curve method.20Immunoblotting
Western blots were performed as described.14 a-ATF6
antibody was purchased from Acris (Rockville, MD) (SM7007P),
a-GRP78 from Abcam (Cambridge, UK) (ab21685), a-ATG16L1
from CST (Danvers, MA) (#8089), GRP94 from CST (#2104), a-
p100/p52 from CST (#52583), a-p-p65 from Abcam
(ab86299), a-p65 from CST (#82429, a-p38, and a-p-p38 from
CST (#9212 and #9211, respectively).


















ATHistopathological Analyses of Murine SI Tissue
Histological scoring was performed in a blinded fashion.
The histological score displays the combined score of inflam-
matory cell infiltration, cell death (TUNEL) and tissue damage
as described elsewhere.5Mice
Villin(V)-creþ; Xbp1fl/fl (Xbp1DIEC), Villin(V)-creþ; Atg16l1fl/fl
(Atg161DIEC) 5 mice, backcrossed for at least 6 generations on a
C57BL/6 background, were used at an age of 8 to 20 weeks. All
mice were maintained in a specific pathogen-free facility. All
experiments were performed in accordance with the guidelines
for Animal Care of Kiel University and in conformity to national
and international laws and policies and with appropriate per-
missions (acceptance no. V242–7224.121–33).In Vivo Treatment of Mice
Atg16l1DIEC or Atg16l1fl/fl mice were treated with 1mg/kg
bodyweight tunicamycin or dimethyl sulfoxide intraperitone-
ally (IP) for 24 hours or 72 hours before being killed. Groups of
mice received 2.5 mg/g bodyweight Triacsin C (TC) or 40 mg/g
bodyweight CX-4945 IP, respectively, at 0, 24, and 48 hours
post tunicamycin injection (72-hour experiment) or once at
0 hour (24-hour experiment). This animal experiment was
approved by the Animal Investigation Committee of the Uni-
versity Hospital Schleswig-Holstein (acceptance no. V242–
32647/2018 [59–7/18]).Statistics
Statistical analysis was performed using the GraphPad
Prism 5 software package (GraphPad Software Inc., La
Jolla, CA). Unless otherwise stated, the Student unpaired t
test was performed. Data are shown as mean ± standard
error of the mean (SEM). In case multiple groups were
compared, the analysis of variance with post hoc Tukey’s
test was used for statistical analysis. A P value of  .05
was considered as significant (*). A P value of  .01
was considered as strongly significant (**) and P value
of  .001 as highly significant (***). **** indicates
P value  .0001.=
Figure 2. CSNK2B controls ATF6a signaling upstream of intram
ACSL1 (siACSL1), CSNK2B (siCSNK2B), and ATF6a (siATF6) in
ERSE promoter activity quantified by dual luciferase reporter
tunicamycin (TM) for additional 24 hours. (B) mRNA levels of ATF
3) 24 hours after TM stimulation. (C) Effects of TC and TBB treat
dual luciferase reporter assays. Cells transfected either with N-
tunicamycin and inhibitors (24 hours). (D and E) Transcript levels
SI organoids treated with tunicamycin (0.1 mg/mL) and TC (D) o
lipofectamine-complexed Palmitoyl coenzyme A (100 mM) or lipo
reporter activity was measured. (G) ERSE promoter activity
(siSEC31a). (H) ER-Golgi transport was inhibited in Caco-2 cells
TBB, respectively. Cells stimulated for 24 hours. ERSE promote
data representative of 3 independent experiments. For statistica
hoc test was performed.Results
Identification and Network Analysis of ATF6a
Signaling Modulators
To identify modulators of the ATF6a signaling pathway,
we targeted 7783 genes using a commercially available
“druggable” genome siRNA library. The screen was per-
formed in human embryonic kidney cells (HEK-293) trans-
fected with siRNA and a luciferase reporter construct driven
by an ATF6-specific ERSE cassette (Figure 1A).4 Luciferase
activity was measured 24 hours after stimulation with the
ER-stress inducer tunicamycin (5 mg/mL), which inhibits N-
glycosylation. Each transcript was targeted using 3 different
siRNAs, resulting in a total number of 23,349 assays for
ATF6 activation (Figure 1B). Genes with a normalized,
averaged fold-induction higher than 2.0 or lower than 2.0
were considered as candidate genes. To validate the find-
ings, the 157 genes (Supplementary Table 1A) were
rescreened using the same experimental setup. The
remaining 104 candidate genes (Supplementary Table 1B)
were subjected to a third screen using pools of 4 indepen-
dent siRNAs per transcript (Figure 1B). This stringent
approach resulted in 22 hits (Supplementary Table 1C),
comprising 15 suppressors and 7 activators of ATF6a
signaling (Figure 1B and C). A protein interaction network
(STRING) analysis revealed an increased connectivity from
the primary to the tertiary screen (primary screen: average
local clustering coefficient 0.367, P value 0.00147; third
screen: 0.469 and 1.15  10–8, respectively).Validated siRNA-mediated Cellular ER-stress
Regulation by Selected Individual Candidates Is
Phenocopied by Chemical Interference
From the regulatory network of 22 validated ATF6a
signaling modulators, we selected 6 candidates for further
functional characterization based on their (1) known bio-
logical function, (2) cellular localization (ER, Golgi, nucleus),
(3) availability of specific inhibitors/inducers, (4) antibody
availability, and (5) available mouse models
(Supplementary Figure 1B, Supplementary Table 1D). To
independently validate the siRNA-mediated effects, we usedembrane cleavage. (A and B) siRNA-mediated knockdown of
Caco-2 cells. Scrambled ¼ nontargeting control siRNA. (A)
assays. After 24 hours, cells were stimulated with 5 mg/mL
6a target HSP90B1 were measured by quantitative PCR (n ¼
ment on ERSE promoter activity in Caco-2 cells quantified by
ATF6a or with the empty plasmid (blue) and stimulated with
of Hsp90b1 and Hspa5 in WT and Atf6a transgenic (Atf6 tgtg)
r TBB (E) for 24 hours. (F) Caco-2 cells were stimulated with
fectamine alone (Lipo) for 24 hours and ERSE dual luciferase
in Caco-2 cells on siRNA-mediated depletion of SEC31a
with FLI-06 (1 mM) in presence or absence of tunicamycin and
r activity quantified by dual luciferase reporter assay. Shown
l analysis, 1-way analysis of variance together with Tukey post


















ATcorresponding chemical inhibitors or inducers (Figure 1E–
H). Direct inhibition of the identified ATF6a signaling in-
ducers ACSL1 (Acyl-CoA Synthetase Long Chain Family
Member 1) and CSNK2B (Casein Kinase 2b) using TC and
4,5,6,7-Tetrabromo-2-azabenzimidazole (TBB), respectively,
significantly reduced ERSE promoter activity upon ER-
stress induction (Figure 1E). Treatment of cells with
N,N,N0,N0-Tetrakis (2-pyridylmethyl)ethylenediamine
(TPEN), a Zn2þ chelator, known to increase the expression
of the identified ATF6a inducer SLC30A3,21 elevated the
activity of the ATF6a (Figure 1F). Inhibition of the serine
protease 8 (PRSS8) activity by Camostat mesylate (CM)
augmented ATF6a signaling (Figure 1G). Indirect inhibition
of RTN4IP1 (Reticulon 4 Interacting Protein 1) signaling
with Simvastatin (Sim), which blocks RhoA signaling, a
downstream target of RTN4 (Reticulon 4)22 verified
RTN4IP1 as a repressor of ATF6a signaling (Figure 1G).
Treatment of cells with the VDAC2 (voltage dependent
anion channel 2) binding small molecule Erastin, known to
induce VDAC2 expression,23 diminished ATF6a signaling
and confirmed VDAC2 as repressor of this signaling branch
(Figure 1H).ACSL1 and CSNK2B Act on Distinct Steps of
ATF6a Signaling in IECs
To further confirm the relevance of ACSL1 and CSNK2B
in the intestinal epithelium, we silenced ACSL1 and CSNK2B
in the Caco-2 cells using siRNA transfection (for knockdown
efficiency, see Supplementary Figure 2A). This resulted in
significantly reduced ERSE promoter activity (Figure 2A)
and reduced messenger RNA (mRNA) levels of the canonical
ATF6a-target gene HSP90B1 (GRP94) after tunicamycin
stimulation (Figure 2B).
To address the molecular mechanism how ACSL1 and
CSNK2B act on ATF6a signaling, we first transfected Caco-
2 cells either with a plasmid encoding the transcription-
ally active N-terminal ATF6a fragment.24 In this model,
influence of an inhibitor would point to an effect down-
stream of the S1/2P-dependent intramembrane proteoly-
sis of ATF6a. We found that ACSL1 inhibition by TC
repressed ERSE activation in cells overexpressing N-ter-
minal ATF6a, whereas treatment with the CSNK2B inhib-
itor TBB did not inhibit ERSE-dependent reporter gene
activity (Figure 2C). Similarly, in intestinal organoids
derived from transgenic mice overexpressing the activated
form of ATF6a (Villin-Cre::nAtf6a tg carrying a loxP-STOP-
loxP cassette in front of the transgene, termed Atf6tgtg=
Figure 3. ATF6a regulates NF-kB signaling on ER-stress induc
transcript levels of in WT and Atf6a transgenic (Atf6 tgtg) SI org
Cxcl1 and Tnfa mRNA levels in WT and Atf6 tgtg SI organoids
Caco-2 cells on (C) inhibition of S1P with PF-429242 (10 mM)
(siACSL1), or CSNK2B (siCSNK2B). (E) NF-kB dual luciferase r
complexed Palmitoyl coenzyme A (100 mM) or lipofectamine al
dependent experiments. Statistical analysis was performed usin
test.hereafter),24 TBB treatment did not diminish mRNA levels
of Atf6a target genes (Hsp90b1, Hspa5) upon ER-stress
induction by tunicamycin and at baseline. In contrast, in-
hibition of ACSL1 with TC resulted in reduced mRNA
levels of Hsp90b1 (Grp94) and Hspa5 (Grp78) (Figure 2D
and E). These results imply that ACSL1 mediates its co-
activating effect on ATF6a signaling downstream of the
cleavage event at the Golgi apparatus. Treatment of IECs
with Palmitoyl coenzyme A, product of the enzymatic re-
action catalyzed by ACSL1, caused increased ERSE re-
porter activity (Figure 2F) supporting the role of ACSL1 as
inducer of ATF6a signaling. Importantly, the lack of effect
of the CSNK2B inhibitor TBB on Atf6tgtg-induced signaling
implies that CSNK2B regulates ATF6a signaling upstream
of the intramembrane proteolysis. Koreishi et al25
demonstrated previously that the casein kinase 2 (CK2),
composed of CSNK2B and CSNK2A, phosphorylates the
COPII constituent Sec31, thereby facilitating ER-Golgi
trafficking. As it was shown that ATF6a trafficking is
dependent on COPII vesicles,26 we hypothesized that
CSNK2B might be involved in the transport of ATF6a from
the ER to the Golgi apparatus. Indeed, depletion of SEC31
by siRNA in IECs abolished the inhibitory effect of TBB on
ERSE reporter gene activity (Figure 2G). In further sup-
port of these findings, inhibition of ER-Golgi trafficking by
treatment with the dihydropyridine FLI-06 (1 mM)27
diminished the effect of CSNK2B inhibition on ERSE pro-
moter activity (Figure 2H).The ATF6a Branch of the UPR is a Critical
Modulator of ER-Stress–Induced
Proinflammatory Signals in IECs
Unresolved ER stress in IECs has emerged as an
important mechanism favoring intestinal inflammation.8
First, we examined the levels of proinflammatory cyto-
kines in intestinal organoids derived from Atf6tgtg trans-
genic mice and littermate control mice. Atf6tgtg organoids
displayed an elevation of transcript levels of Cxcl1 and Tnfa
in the presence of tunicamycin, confirming a co-activating
role of nATF6a (Figure 3A). Levels of the ER stress target
gene transcripts (Hspa5 and Hsp90b1) as well as the ATF6
transcript itself could also be synergistically increased by
tunicamycin stimulation in Atf6tgtg transgenic organoids.
We detected, both on mRNA and on protein level, altered
expression of canonical and noncanonical NF-kB signaling
components, indicated by increased levels of Rela and p-p65tion. (A) Cxcl1, Tnfa, Hspa5 (Grp78), Hsp90b1 (Grp94), Atf6
anoids stimulated with tunicamycin (100 ng/mL, 24 hours). (B)
stimulated for 24 hours. (C and D) NF-kB promoter activity in
or (D) siRNA-mediated depletion of ATF6a (siATF6), ACSL1
eporter assay in Caco-2 cells stimulated with lipofectamine-
one (Lipo) for 24 hours. Depicted data representative of 3 in-
g one1way analysis of variance together with post hoc Tukey


















ATlevels and increased levels of Relb, Nfkb2, p100, and p52,
respectively (Supplementary Figure 2B and C) already at
baseline. This was accompanied by enhanced phosphoryla-
tion of p38 (Supplementary Figure 2C) in the Atf6tgtg
organoids. In line with these findings, inhibition of NF-kB
signaling using the aromatic diamine JSH-23, which blocks
the nuclear translocation of NF-kB,28 abolished the proin-
flammatory signature in organoids overexpressing the N-
terminal ATF6 fragment illustrated by significantly reduced
mRNA levels of both Cxcl1 and Tnfa upon ER-stress induc-
tion (Figure 3B). As ER-stress dependent activation of
proinflammatory signals might involve autocrine release of
TNFa5, we employed an anti-TNF neutralizing antibody
(100 ng/mL) in Atf6tgtg organoids, which, however, only
had mild effects on the mRNA levels of these proin-
flammatory cytokines and 2 NF-kB target genes (Birc2/3)29
(Figure 3B, Supplementary Figure 2D). Of note, whereas it
has been shown that a ENU-induced hypomorphic mutation
of the S1P gene renders mice susceptible to colitis,30 phar-
macological inhibition of S1P required for ATF6a cleavage
at the Golgi complex with PF-429242 (10 mM) was able to
inhibit tunicamycin-induced NF-kB reporter activation
(Figure 3C). To further validate this finding, we performed
siRNA knockdown of ATF6a, ACSL1, or CSNK2B in IECs and
could confirm the co-activation effect of the endogenous
ATF6 signaling module on NF-kB reporter gene activity on
ER-stress induction (Figure 3D). In agreement with these
findings, stimulation with the ACSL1 product Palmitoyl co-
enzyme A caused increased NF-kB reporter gene activity
(Figure 3E). Taken together, our results identify ATF6 as a
critical regulator of proinflammatory signaling in IECs and
suggests a functional interaction of NF-kB and ATF6
signaling under conditions of ER stress.Inhibition of the ATF6a Activators CSNK2B and
ASCL1 Attenuates the Proinflammatory Profile of
Genetically Induced ER stress: Impact of ATF6a
Signaling on Xbp1- and Atg16l1-deficiency
We next turned our attention to a potential role of
ATF6a and its upstream regulators for the execution of
impaired, proinflammatory ER-stress responses observed in
Xbp1- and Atg16l1-deficient IECs.5,8,13,14 Indeed, Caco-2 cells
carrying a genetic deletion of the autophagy gene ATG16L1
introduced by CRISPR-Cas914 (DATG16L1-Caco-2) exhibited
increased ATF6a cleavage compared to their respective WT=
Figure 4. Reduction of the hyperactivation of the ATF6a branch
cytokines. (A) Western blot analysis and quantification (B) of
tunicamycin (5 mg/mL, 6 hours). #1 to #4 refers to 4 independ
Effects of TC and (D) TBB on the ERSE promoter in Caco-2 cell
Caco-2 WT and DATG16L1-deficient cells quantified by MTS a
stimulation (5 mg/mL, 24 hours). (G-H) NF-kB Luciferase activity
with tunicamycin (5 mg/mL, 24 hours) in the presence or abse
transcript levels in SI organoids (Atg16l1fl/fl, Atg16l1DIEC) treated
Shown data representative of 3 independent experiments. Statis
together with Tukey post hoc test.comparators (WT-Caco-2) (Figure 4A and B). In addition,
the ERSE reporter assays revealed significantly increased
activation of the ATF6a branch in DATG16L1 cells compared
with WT (Figure 4C), both at baseline and on further ER-
stress induction with tunicamycin (5 mg/mL). Likewise,
Atg16l1-deficient SI organoids showed an up-regulation of
ATF6 target genes compared with WT controls
(Supplementary Figure 3A). Tunicamycin-induced ERSE re-
porter activity and target gene induction could be blocked
by the cognate inhibitors TC (ACSL1) or TBB (CSNK2B),
respectively (Figure 4C and D). In addition, cell viability of
DATG16L1 cells on ER-stress induction-assessed by MTS
assay was significantly improved by treatment with the 2
ATF6 inhibitors (Figure 4E and F). Next, we sought to study
the effect of inhibition of the ATF6a branch on the increased
NF-kB signaling tone in autophagy-deficient IECs.31
DATG16L1-Caco2 cells transfected with an NF-kB reporter
plasmid showed increased activity upon tunicamycin stim-
ulation compared with WT cells (Figure 4G and H). Notably,
treatment with TBB/TC again significantly reduced NF-kB
reporter gene activity. Increased mRNA levels of Cxcl1 and
Tnfa observed in the Atg16l1-deficient organoids were
reduced on treatment with the ACSL1 and the CSNK2B in-
hibitor, respectively (Figure 4I).
We also found elevated activation of the ATF6a arm in
the SI epithelial cell line MODE-K stably transduced with a
short hairpin Xbp1 (shXbp1) lentiviral vector (Figure 5A–C,
Supplementary Figure 3C).5 We detected enhanced mRNA
levels of ATF6a targets (Hsp90b1, Hspa5) in Xbp1-deficient
SI organoids (Supplementary Figure 3B). Inhibition of
ATF6a signaling by treatment with TC or TBB alleviated
ERSE promoter activity (Figure 5C and D) and improved cell
viability on ER-stress induction in MODE-K.iXbp1 (DXbp1)
cells (Figure 5E and F). Moreover, both augmented NF-kB
activity (Figure 5G and H) in DXbp1 cells, and Cxcl1 and Tnfa
levels in Xbp1-deficient organoids (Figure 5I) were reduced
in the presence of the inhibitors on tunicamycin treatment
compared with controls.
We next assessed the contribution of ATF6a signaling to
the ileitis phenotype of Atg16l1DIEC mice in a short-term (24
hours, Supplementary Figure 4) and in a longer in vivo ER
stress model, in which mice were followed up for 72 hours
(Figure 6). In both experiments, Atg16l1fl/fl and Atg16l1DIEC
mice were injected IP with a single dose of tunicamycin (1
mg/kg body weight) at 0 hour. To block ATF6a-mediated
signaling, mice were simultaneously injected with either TCin ATG16L1-deficient IECs alleviates levels of proinflammatory
DATG16L1-Caco-2 and the WT cells. Cells stimulated with
ent biological replicates derived from one CRISPR clone. (C)
s measured by dual luciferase reporter assays. Cell viability of
ssay in the presence of TC (E) and TBB (F) after tunicamycin
in Caco-2 WT and ATG16L1-deficient cells. Cells stimulated
nce of (G) TC (5 mM) or (H) TBB (10 mM). (I) Cxcl1 and Tnfa
with tunicamycin (100 ng/mL) and TC/TBB (24 hours, n ¼ 3).
tical analysis was performed using 1-way analysis of variance


















ATor CX-4945 (silmatasertib) at 0 hour, and in addition at 24
hours, and 48 hours post tunicamycin injection in case of
the 72-hour experiment (see Figure 6A and Supplementary
Figure 5A for experimental design). Similar to TBB, CX-4945
is an ATP-competitive inhibitor of the CK2 and inhibited
ATF6-mediated ERSE and NF-kB reporter gene activity in
DATG16L1-Caco-2 cells (Supplementary Figure 3D and E).
However, superior to TBB, CX-4945 is orally bioavailable32
and is currently tested in clinical trials for hematological
and solid cancer treatment (ClinicalTrials.gov
NCT01199718, NCT02128282, NCT00891280). Both TC
and CX-4945 injections significantly attenuated
tunicamycin-mediated body weight loss after 72 hours in
Atg16l1DIEC mice (Figure 6B, Supplementary Figure 5A).
Moreover, we observed attenuated shortening of the small
intestine (Figure 6C), reduced Cxcl1 protein levels in the
serum (Figure 6D) of Atg16l1DIEC mice, and reduced mRNA
levels of Tnfa and Ifit1 on tunicamycin injection in the
presence of the tested inhibitors (Supplementary Figure 5B
and C). Both transcripts are known to be induced by ER
stress signals in Atg16l1DIEC mice.14 Likewise, histological
analysis demonstrated reduced levels of inflammation
(Figure 6G) and reduced epithelial cell death as depicted by
reduced numbers of TUNELþ epithelial cells in Atg16l1-
deficient IECs in the presence of the tested inhibitors
(Figure 6E and F). Staining was concentrated at the bottom
of the crypts and, in line with previous studies, marked
Paneth cells as well as other epithelial cells.14,33 In line with
these findings, already 24 hours after tunicamycin injection,
TC and CX-4945 treatment resulted in reduced epithelial
cell death in the absence of Atg16l1 as assessed by TUNEL
staining (Supplementary Figure 4D and E), and reduced
mRNA levels of Tnfa and Ifit1 (Supplementary Figure 4F).
Limiting ATF6a Signaling Attenuates the
Proinflammatory Profile in Human Organoids on
ER-stress Induction: Relevance for Human IBD
We next assessed expression levels and activation of
ATF6 in human patients with IBD. Analysis of mRNA level in
purified IECs from ileal biopsies revealed significantly
higher expression of ATF6a and the ATF6 target HSPA5 in
pediatric patients with CD compared with healthy controls
(Figure 7A, comparison with ulcerative colitis in
Supplementary Figure 6B).34 Likewise, CSNK2B, but not
ACSL1 mRNA levels were upregulated (Supplementary=
Figure 5. Inhibition of the ATF6a branch in Xbp1-deficient IECs
blotting and quantification (B) of MODE-K cells stably transduce
WT control. Cells stimulated with tunicamycin (5 mg/mL, 6 hours
D) Activation of the ATF6a branch upon ER-stress induction (tun
and (D) TBB in MODE-K.iXbp1 (DXbp1) and MODE-K.iCtrl (WT)
TBB (F) on cell viability quantified by MTS assay after exposure
and H) NF-kB luciferase activity in WT and Xbp1-deficient Mode
the presence or absence of (G) TC (5 mM) or (H) TBB (10 mM). (I)
Xbp1DIEC) treated with tunicamycin (100 ng/mL) and inhibitors
representative of 3 independent experiments. For statistical ana
test was performed.Figure 6B). Using protein lysates of early-passage ileal hu-
man organoids from patients with CD and healthy controls,
we next demonstrated higher levels of the active p36 frag-
ment of ATF6a in organoids derived from adult patients
with CD, which was more pronounced in organoids from
inflamed tissue (Figure 7B, Supplementary Figure 6A,
Supplementary Table 2). Next, we analyzed mRNA levels of
ATF6 targets in human organoids generated from biopsies of
patients with CD and healthy controls. On tunicamycin-
mediated ER stress induction, we detected significantly
increased levels of HSPA5, DNAJC3, and HSP90B1 in orga-
noids derived from patients with CD compared with healthy
controls (Figure 7C). Subsequently, we investigated in hu-
man ileal organoids whether ATF6a signaling can be limited
by ACSL1- or CSNK2B inhibition. Indeed, exposure to either
TC (Figure 7D) or TBB (Figure 7E) resulted in significantly
reduced expression of ATF6a targets on exposure to tuni-
camycin. Importantly, inhibition of ATF6a signaling by TC or
TBB, respectively, resulted in significantly lower mRNA
expression of proinflammatory cytokines (IL8, TNFa) in
human organoids exposed to tunicamycin (Figure 7F and G).
Discussion
In this study, we identified regulators of ATF6a signaling
using a stringent siRNA screening approach. Among the 22
validated upstream regulators of ATF6a, ACSL1 and CSNK2B
were further analyzed. ACSL1 (acyl-CoA synthetase long
chain family member 1) is a 78-kDa intrinsic membrane
protein that mediates the conversion of fatty acids to acyl-
CoAs. Importantly, ACSL1 localizes to the ER and to
mitochondria-associated membranes. The other identified
ATF6a co-activator CSNK2B encodes the regulatory subunit
of the CK2, which is a tetrameric serine/threonine-selective
protein kinase composed of 2 catalytic subunits and 2 reg-
ulatory subunits. CK2 is localized in the ER and the Golgi
complex.35 Several studies have described a modulatory
function of the CK2 on the UPR.36,37 However, to our
knowledge, none of these studies have provided a mecha-
nistic link between the ATF6a branch of the UPR and
CSNK2B. Using transgenic organoids overexpressing a
constitutively active ATF6a form, which mimics the S1P-
cleaved protein, we show that the 2 targets act either
downstream (ACSL1) or upstream (CK2) of the cleavage
event. It is important to note that pharmacological inhibition
of the upstream ATF6a regulators did not completelyalleviates levels of proinflammatory cytokines. (A) Immuno-
d with a short hairpin Xbp1 lentiviral vector and the respective
). #1 to #4 refers to 4 independent biological replicates. (C and
icamycin, 24 h, 5 mg/mL) quantified in the presence of (C) TC
cells by dual luciferase reporter assays. Effects of TC (E) and
to tunicamycin (5 mg/mL, 24 hours) in WT and DXbp1 cells. (G
-K cells. Cells exposed to tunicamycin (5 mg/mL, 24 hours) in
Quantitative PCR of Cxcl1 and Tnfa of SI organoids (Xbp1fl/fl,
(TC 5 mM; TBB 10 mM) for 24 hours (n ¼ 3). Data shown are
lysis, 1-way analysis of variance together with Tukey post hoc


















ATabolish all tunicamycin-mediated ER stress effects. This
could be due to incomplete abrogation of ATF6a signals by
the inhibitors, but also due to the extensive crosstalk be-
tween the 3 UPR branches,1,38 which should be carefully
considered when targeting the UPR for therapeutic benefit.
Several studies have revealed an intensive crosstalk
between unresolved ER stress, failing autophagy and
proinflammatory signaling in IECs in the context of
IBD.5,8,13,14,39 In Xbp1- and Atg16l1-deficient IECs, increased
TNF-dependent NF-kB signaling and spontaneous intestinal
inflammation in vivo are observed and have been attributed
to elevated IRE1a levels.5,8,13 In this context, our study re-
veals a significantly increased activation of the ATF6a
branch in cells lacking the autophagy gene Atg16l1 or the
UPR gene Xbp1. Importantly, inhibition of ATF6a upstream
signaling using the small molecule inhibitors TC/TBB was
able to diminish the observed hyperinflammatory pheno-
type of Atg16l1- and Xbp1-deficient cells.5,13 Interestingly,
direct activation of ATF6a by active IRE1 has been pro-
posed40 and our data suggest a role of ATF6a and its up-
stream regulators for the execution of impaired,
proinflammatory ER-stress responses in IECs. It has been
proposed that ATF6a induces the phosphorylation of AKT to
finally activate NF-kB signaling,41,42 but engagement of
other proinflammatory signaling events (eg, the activation
of p38MAPK) have also been reported during ER stress.43
As MAPK activation has been shown to shift the balance
of NF-kB signals in IECs from an antiapoptotic to a proin-
flammatory function,44 such additional signals could be
important for the effector function of ATF6 itself or might be
modulated by downstream effectors of ATF6a.
In line with a co-activating role of ATF6 on the NF-kB
pathway, we demonstrate an up-regulation of components
of the NF-kB machinery (NF-kB2 coding for p100 and its
processed form p52) and increased p65 as well as
p38MAPK phosphorylation in organoids overexpressing the
active N-terminal ATF6a fragment already under steady-
state conditions. It must be noted that this model only
incompletely reflects the physiological situation of normal
ATF6 activation as the organoids face a constant stimulation
by the transgene-encoded transcription factor; however
under additional stimulation with the ER stress inducer
tunicamycin, synergistic induction of Cxcl1 and Tnfa mRNA
levels was still observed. The induction of the 2 transcripts
could be blocked by an inhibitor of the nuclear translocation
of p65,28 whereas it was only partially inhibited by appli-
cation of anti-TNF antibodies arguing against a main role of
autocrine TNF release in this system.=
Figure 6. Inhibition of the ATF6a branch mitigates ER-stress m
Stimulation scheme of Atg16l1fl/fl and Atg16l1DIEC mice (n ¼ 4–7
IP, when indicated mice additionally received either TC (2.5 mg/g
48 hours. Control groups received dimethyl sulfoxide. After 72 h
(C) SI length 72 hours after injection. (D) CXCL1 concentration in
and F) TUNEL staining of SI sections with representative picture
cell/stem cell niche) and quantification (F). Bars ¼ 20 mm. A min
group. (G) Histological evaluation of small intestinal sections.
variance together with Tukey post hoc test.We have shown that homozygous Atf6tgtg mice develop
spontaneous colon adenomas at 12 weeks of age.24
Increased proinflammatory cytokine mRNA levels in this
model were only detected at late stages of tumor develop-
ment in whole colon tissue (>20 weeks) supporting the
hypothesis that ATF6a activation alone is not sufficient to
generate IBD-like tissue pathology, but additional signals
must be present. As tunicamycin inhibits N-linked protein
glycosylation and thereby activates additional ER stress
signaling at the level of all 3 UPR branches,45 which in-
cludes IRE1-dependent signaling, the results suggest that
the ATF6a branch serves as a co-activating executioner
toward a hyperinflammatory phenotype. Pharmacological
inhibition of the 2 ATF6a upstream activators CSNK2B and
ASCL1 on tunicamycin application in vivo was able to block
ER stress-induced epithelial cell death and signs of mucosal
inflammation in the SI. The protective effect was more
pronounced in mice lacking Atg16l1 in the intestinal
epithelium, which are prone to develop ileal inflammation
dependent on IRE1 and the TNFR1-NF-kB axis5,13 and to
TNF-dependent necroptosis.33 Still, it remains an inter-
esting question whether and how ATF6a acts upon the
autophagic flux of IECs under autophagy-proficient
conditions.
These observations in the SI are important for human IBD,
as the role of ATF6a signaling in intestinal inflammation has
only been shown in colonic IECs from patients with ulcerative
colitis, where increased cleavage of ATF6a and augmented
expression of the ATF6a targets GRP78 and GRP94 were
demonstrated.12 Increased ATF6a expression itself was
recently suggested as a marker for precancerous dysplasia in
colitis-associated colorectal cancer.46 Here, we show that
increased mRNA levels and activation of the ATF6 branch are
present in SI epithelial cells from patients with CD. This
activatability is maintained, at least during early passages, in
patient-derived small intestinal organoids, arguing for a sus-
tained deregulation of this pathway in this disease condition.
It is important to note that, although the hypomorphic
ATG16L1T300A variant is a risk factor for ileal CD,47 it seems
unlikely that small intestinal ATF6 hyperactivation can be
explained by genetics only. ER stress rather should be
regarded as a central hub integrating signals on the state of
the cell.48 As such it is influenced by a variety of environ-
mental factors, such as diet,49 microbiota,50 or proliferative
signals14,51 that act on IECs as a barrier constituent. The in-
dividual life history of exposure to such stressors may exceed
the epithelium’s resilience leading to unresolved ER stress
and ATF6 activation as a proinflammatory signal, wherebyediated inflammation and cell death in Atg16l1DIEC mice. (A)
). Mice were treated with 1 mg/kg bodyweight of tunicamycin
bodyweight) or CX-4945 (40 mg/g body weight) at 0, 24, and
ours mice were killed. (B) Weight loss 72 hours after injection.
serum quantified by enzyme-linked immunosorbent assay. (E
s (E, arrowheads denote TUNELþ IECs outside of the Paneth
imum of 50 crypts/intestine were assessed in each treatment
Statistical analysis was performed using 1-way analysis of


















AThypomorphic ATG16L1T300A may be an important determi-
nant of the threshold.
Our findings suggest that engagement of the ATF6a
branch may represent an executioner mechanism of proin-
flammatory ER stress signals, particularly in IECs with
defective autophagy or exaggerated UPR signaling. We
demonstrate the presence of activated ATF6 signaling as a
characteristic feature of small intestinal IECs isolated from
patients with CD. Importantly, we show that inhibition of
the ATF6 branch is able to mitigate the proinflammatory
signature of ER stress induction in human small intestinal
organoids. Interfering with the ATF6a pathway targeting
the upstream inducers ACSL1 and CSNK2B, respectively,
might thus represent a novel therapeutic approach in in-
testinal inflammation.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
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Supplementary Material and Methods
Cell Culture and Reagents
Human embryonic kidney (HEK) 293 cells (ACC 305),
and human colonic carcinoma Caco-2 (ACC 169) cells were
purchased from the German Collection of Microorganisms
and Cell Cultures (DSMZ, Braunschweig, Germany).
Camostat mesylate, FLI-06 and Simvastatin were pur-
chased from Sigma-Aldrich (St Louis, MO). Erastin and
TPEN were from Cayman (Ann Arbor, MI), TBB from Tocris
(Bristol, UK), and CX-4945 from (Biomol, Hamburg, Ger-
many). Triascin C was purchased from Enzo Life Sciences
(Farmingdale, IL).
Cultivation of Murine SI Organoids
Crypts were isolated from mouse SI by EDTA-based
Ca2þ/Mg2þ chelation and intestinal organoids were culti-
vated as described by Sato et al.1 In brief, SI was removed
and cut longitudinally. Intestinal pieces were incubated in
phosphate-buffered saline supplemented with 10 nM EDTA
for 10 minutes intermitted by shaking. Supernatant was
removed and phosphate-buffered saline–EDTA solution was
added. This procedure was repeated 4 times. The crypt
suspension was passed through a 100-mm strainer and
centrifuged at 400 g. Epithelial crypts were resuspended in
Matrigel (BD Bioscience, San Jose, CA) and embedded in 24-
well plates and cultivated in IntestiCult Organoid Growth
Medium (STEMCELL; Vancouver, Canada). Medium was
changed twice per week and organoids were stimulated
after 7 days of cultivation. The mouse model for the SI
organoids from Atf6tgtg and tg/wt and controls (Atf6 wt/
wt) were described in Coleman et al.2
Culture of Human Intestinal Organoids
Human intestinal biopsy specimens were obtained from
patients who underwent endoscopic examination. The study
was approved by the Ethics Committee of the Medical
Faculty, University Kiel (vote B231/98) and written
informed consent was obtained from each patient before
study-related procedures. Isolation of the crypts and
establishment of intestinal organoids were performed as
described.3 Briefly, crypts were collected by shaking biopsy
specimens in 2.5 mM EDTA. Isolated crypts were embedded
in Matrigel and placed in 24-well culture dish. Crypts were
maintained in 50% L-WRN conditioned medium supple-
mented with recombinant human epidermal growth factor
(50 ng/mL, PeproTech, Hamburg, Germany), Y-27632 (10
mM, Sigma-Aldrich), A83–01 (500 nM, Tocris), Nicotinamide
(10 mM, Sigma-Aldrich), N2 supplement and B12 supple-
ment (Thermo Scientific) and SB202190 (10 mM, Enzo);
50% L-WRN conditioned media was generated as previ-
ously described using the L-WRN cell line.4 Organoids were
passaged every 6 to 7 days. For all experiments, organoids
were used at passage 3 to 5.
Transfection of siRNA and Plasmid DNA
For reverse transfection of siRNA into cultured cells the
polyamine-based transfection agent siPORT Amine (Life
Technologies, Carlsbad, CA) was used according to the
manufacturer’s protocol. For transfection of plasmid DNA
into cultured cells, FuGENE 6 (Promega, Madison, WI) was
used according to the manufacturer’s protocol.
High-throughput RNAi Screening Procedure
A total of 23,349 unique siRNAs targeting 7783 genes
were screened using the Silencer Human Druggable
Genome siRNA library V3 (Ambion, Austin, TX). HEK-293
cells were reverse transfected with either single siRNAs
(Ambion; primary and secondary screen) or siRNA pools
(siGENOME; SMARTpool; Dharmacon, Lafayette, LA; tertiary
screen) complexed with siPORT Amine (Ambion).
Dual Luciferase Reporter Assays
Plasmid-encoded ERSE-dependent firefly luciferase
(pGL3-ERSE, 12 ng/well) and a constitutive thymidine-
kinase driven Renilla luciferase were used in a dual lucif-
erase assay (Clontech, 3 ng/well) to assay ATF6/ERSE
activation. For quantification of the NF-kB promoter activ-
ity, a reporter system based on NF-kB responsive promoter
elements driving expression of the Firefly luciferase (40 ng/
well) was used.5 For all luciferase reporter assays, the fold
change is depicted. For calculating the fold change, unsti-
mulated WT controls were set to 1.
RNA Extracts and Quantitative Real-Time PCR
Total RNA was isolated using the RNeasy kit (Qiagen).
Total RNA was reverse-transcribed to cDNA using the
Maxima H Minus First Strand cDNA Synthesis kit (Thermo
Scientific). Quantitative RealTime PCR was performed using
the TaqMan Gene Expression Master Mix (Applied Bio-
systems) and analyzed by the 7900HT Fast Real Time PCR
System (Applied Biosystems). The following TaqMan assays




Tnf(00443258). Relative transcript levels were determined
using the indicated housekeeper and the standard curve
method.6
Immunoblotting
Cells were lysed in RIPA buffer (Thermo Scientific) in
the presence of protease and phosphatase inhibitors. Pre-
cipitates were separated by SDS/PAGE. After transfer onto
polyvinylidene fluoride membranes (Millipore, Burlington,
MA), Western blots were performed as described.5 a-ATF6
antibody was purchased from Acris (SM7007P), a-GRP78
from Abcam (Cambridge, UK) (ab21685), a-ATG16L1 from
CST (Danvers, MA) (#8089), GRP94 from CST (#2104), a-
p100/p52 from CST (#52583), a-p-p65 from Abcam
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(ab86299), a-p65 from CST (#82429, and a-p38 and a-p-
p38 from CST (#9212 and #9211, respectively).
TUNEL Staining of Murine SI Tissue
Longitudinal ileal sections were fixed in 10% formalin.
Sections of paraffin-embedded ileal Swiss rolls were
deparaffinized with Tyrol substitute (Roth, Karlsruhe, Ger-
many). Slides were subjected to Apop Tag Plus Peroxidase
in situ Apoptosis Detection kit (Millipore). Slides were
examined using a Zeiss (Jena, Germany) AxioImager.Z1
apotome microscope and AxioVision Rel 4.9 software.
Histopathological Analyses of Murine SI Tissue
Histological scoring was performed in a blinded fashion.
The histological score displays the combined score of in-
flammatory cell infiltration and tissue damage as described
elsewhere.7
Mice
Villin(V)-creþ; Xbp1fl/fl (Xbp1DIEC),8 Villin(V)-creþ;
Atg16l1fl/fl (Atg161DIEC)7 mice, backcrossed for at least 6
generations on a C57BL/6 background, were used at an age
of 8 to 20 weeks. All mice were maintained in a specific
pathogen-free facility. All experiments were performed in
accordance with the guidelines for Animal Care of Kiel
University and in conformity with national and international
laws and policies and with appropriate permissions
(acceptance no. V242–7224.121–33).
In Vivo Treatment of Mice
Atg16l1DIEC or Atg16l1fl/fl mice were treated with 1 mg/kg
bodyweight tunicamycin or dimethyl sulfoxide IP for 24 or 72
hours before being killed. Groups of mice received 2.5 mg/g
bodyweight TC or 40 mg/g bodyweight CX-4945 IP, respec-
tively, at 0, 24, and 48 hours post Tunicamycin injection
(72-hour experiment) or once at 0 hour (24-hour experi-
ment). This animal experiment was approved by the Animal
Investigation Committee of the University Hospital Schleswig-
Holstein (acceptance no. V242–32647/2018 [59–7/18]).
Statistics
Statistical analysis was performed using the GraphPad
Prism 5 software package (GraphPad Software Inc., La Jolla,
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CA). Unless otherwise stated, the Student unpaired t test
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the mean (SEM). In case multiple groups were compared,
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for statistical analysis. A P value of  .05 was considered as
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significant (**) and P value of  .001 as highly significant
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Supplementary Figure 1. Systematic siRNA screening identifies modulators of the ATF6 branch. (A) Network of candidate
genes after the primary screen based on STRING. Only interactions with a confidence score >0.4 were considered. P ¼
.00147. (B) Schematic cellular localization of the 6 ATF6a modulators subjected to further functional studies. ATF6 signaling
inducers are depicted in green, inhibitors shown in orange.
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Supplementary Figure 2. Hyperactivation of the non-canonical NF-kB signaling in Atf6 transgenic intestinal organoids. (A)
Knockdown efficiency for ATF6, ACSL1, and CSNK2B in Caco-2 cells was calculated (related to B). Samples treated with the
nontargeting siRNA (siscrambled, unstimulated) were set to 1. (B) Transcript levels of NF-kB signaling components in SI
organoids treated with tunicamycin (TM 100 ng/mL) for 24 hours. (C) Immunoblotting of protein lysates collected from WT and
Atf6 tgtg SI organoids stimulated with Tunicamycin (TM, 100 ng/mL). Relative p-p65, p52, and p-p38 protein levels were
quantified. The average value of the unstimulated WT controls was set to 1. N ¼ 3 biological replicates. (D) cIAP1/Birc2 and
cIAP2/Birc3 mRNA levels in WT and Atf6 tgtg SI organoids stimulated for 24 hours. Related to Figure 3B. Depicted data
representative of 3 independent experiments. For statistical analysis, 1-way analysis of variance together with Tukey post hoc
test was performed.
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Supplementary Figure 3. Hyperactivation of the ATF6a branch in Atg16l1- and Xbp1-deficient small intestinal organoids.
Transcript levels of Atf6a target genes Hsp90b1 (Grp94) and Hspa5 (Grp78) in small intestinal organoids treated with tuni-
camycin (TM, 100 ng/mL) for 24 hours. (A) Atg16l1fl/fl and Atg16l1DIEC SI organoids. n ¼ 4 biological replicates. (B) Xbp1fl/fl and
Xbp1DIEC small intestinal organoids. n ¼ 4 biological replicates. (C) Transcript levels of Xbp1 in Xbp1-deficient MODE-K cells
(n¼ 4). (D) ERSE promoter activity and (E) NF-kB luciferase activity in Caco-2 cells on exposure to tunicamycin (5 mg/mL) for 24
hours in the presence or absence of CX-4945 (3 mM) as indicated. Shown data representative of 3 independent experiments.
For statistical analysis, 1-way analysis of variance together with Tukey post hoc test was performed.
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Supplementary Figure 4. Restriction of the ATF6a branch reduces ER-stress mediated inflammation and cell death in
Atg16l1DIEC mice. (A) Stimulation scheme of Atg16l1fl/fl and Atg16l1DIEC mice (n ¼ 5/6). Mice were treated with 1 mg/kg
bodyweight of tunicamycin IP, when indicated mice additionally received either TC (2.5 mg/g bodyweight) or CX-4945 (40 mg/g
bodyweight). Control groups received dimethyl sulfoxide (DMSO). After 24 hours, mice were killed. (B) Weight loss 24 hours
after injection. (C) CXCL1 concentration in SI crypt lysates detected via enzyme-linked immunosorbent assay. (D and E)
TUNEL staining of SI sections with representative pictures (D) and quantification (E). A minimum of 50 crypts/intestine were
assessed in each treatment group. Bars ¼ 20 mm. Arrowheads show apoptotic Paneth cells. (F) Transcript levels of Tnfa and
Ifit1 in SI crypt lysates of treated Atg16l1fl/fl and Atg16l1DIEC mice after 24 hours. Statistical analysis was performed using 1-
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Supplementary Figure 5. Inhibition of the ATF6a branch reduces ER-stress mediated proinflammatory signaling in
Atg16l1DIEC mice after 72 hours of treatment. Mice received 1 mg/kg bodyweight of tunicamycin IP, when indicated mice were
additionally treated with either TC (2.5 mg/g bodyweight) or CX-4945 (40 mg/g bodyweight) at 0, 24, and 48 hours. Control
groups received dimethyl sulfoxide (DMSO). Mice were killed after 72 hours (n ¼ 4/7). (A) Body weight loss. (B) Transcript levels
of Tnfa and Ifit1 in SI crypt lysates of Atg16l1fl/fl and Atg16l1DIEC mice after 72 hours of treatment. Statistical analysis was
performed using 1-way analysis of variance together with Tukey post hoc test.













































































































Supplementary Figure 6. Enhanced ATF6 signaling in pa-
tients with IBD. (A) Immunoblotting of protein levels of
p36ATF6 and GRP78 derived from SI organoid lysates
generated from healthy (n ¼7), CD noninflamed (n ¼ 8), and
CD inflamed tissue (n ¼ 9). Related to Figure 7B. (B) Relative
mRNA expression of ATF6, HSPA5, ACSL1, and CSNK2B in
IECs from ileal biopsies from pediatric patients with IBD (CD,
n ¼ 10 and UC, n ¼ 11) and healthy controls (n ¼ 11) (data
obtained from Howell et al.9). Differential expression calcu-
lated between control and diseased using DE-Seq2. Statis-
tical analysis was performed using 1-way analysis of variance
together with Tukey post hoc test.
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